[go: up one dir, main page]

MX2019007327A - Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. - Google Patents

Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.

Info

Publication number
MX2019007327A
MX2019007327A MX2019007327A MX2019007327A MX2019007327A MX 2019007327 A MX2019007327 A MX 2019007327A MX 2019007327 A MX2019007327 A MX 2019007327A MX 2019007327 A MX2019007327 A MX 2019007327A MX 2019007327 A MX2019007327 A MX 2019007327A
Authority
MX
Mexico
Prior art keywords
preparing
salts
hoxy
thiazolidinedione
pyridinyl
Prior art date
Application number
MX2019007327A
Other languages
English (en)
Other versions
MX379709B (es
Inventor
Maria Garcia Collazo Ana
Nicolaas Koek Johannes
Ten Hoeve Wolter
B M Rewinkel Johannes
DE WILDE Sander
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2019007327A publication Critical patent/MX2019007327A/es
Publication of MX379709B publication Critical patent/MX379709B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona un proceso para preparar el compuesto de la Fórmula I, y sus sales farmacéuticamente aceptables; y el proceso de hacer el intermediario de la Fórmula III: en donde PG es como se define como se establece en la especificación.
MX2019007327A 2016-12-23 2017-12-22 Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. MX379709B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
MX2019007327A true MX2019007327A (es) 2019-09-02
MX379709B MX379709B (es) 2025-03-11

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007327A MX379709B (es) 2016-12-23 2017-12-22 Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.

Country Status (18)

Country Link
US (2) US11124505B2 (es)
EP (1) EP3559010B1 (es)
JP (2) JP7294661B2 (es)
KR (1) KR102609373B1 (es)
CN (1) CN110198945B (es)
BR (1) BR112019012972B1 (es)
CA (1) CA3046744A1 (es)
DK (1) DK3559010T3 (es)
ES (1) ES2926580T3 (es)
HR (1) HRP20221067T1 (es)
HU (1) HUE059604T2 (es)
IL (1) IL267557B (es)
LT (1) LT3559010T (es)
MX (1) MX379709B (es)
PL (1) PL3559010T3 (es)
PT (1) PT3559010T (es)
SI (1) SI3559010T1 (es)
WO (1) WO2018116281A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012972B1 (pt) 2016-12-23 2023-04-18 Minoryx Therapeutics S.L Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos
KR20210031867A (ko) 2018-06-06 2021-03-23 미노릭스 테라퓨틱스 에스.엘. 5-[[4-[2-[5-아세틸피리딘-2-일]에톡시]벤질]-1,3-티아졸리딘-2,4-디온 및 이의 염의 용도
SI3801515T1 (sl) 2018-06-06 2025-07-31 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni
JP7549344B2 (ja) 2018-06-06 2024-09-11 ミノリックス セラピューティクス エセ．エレ． 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
ATE447414T1 (de) 2005-02-16 2009-11-15 Micromet Ag Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2149550A4 (en) * 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
JP6101343B2 (ja) * 2012-04-26 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
HUE039555T2 (hu) 2014-04-02 2019-01-28 Minoryx Therapeutics S L 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében
BR112019012972B1 (pt) 2016-12-23 2023-04-18 Minoryx Therapeutics S.L Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos

Also Published As

Publication number Publication date
US20220204496A1 (en) 2022-06-30
SI3559010T1 (sl) 2022-10-28
JP2020502228A (ja) 2020-01-23
MX379709B (es) 2025-03-11
EP3559010B1 (en) 2022-06-08
PT3559010T (pt) 2022-09-01
US11731963B2 (en) 2023-08-22
JP2023052918A (ja) 2023-04-12
ES2926580T3 (es) 2022-10-27
CA3046744A1 (en) 2018-06-28
DK3559010T3 (da) 2022-08-15
US11124505B2 (en) 2021-09-21
US20190389852A1 (en) 2019-12-26
EP3559010A1 (en) 2019-10-30
HUE059604T2 (hu) 2022-11-28
WO2018116281A1 (en) 2018-06-28
IL267557B (en) 2021-10-31
BR112019012972B1 (pt) 2023-04-18
KR20190100300A (ko) 2019-08-28
CN110198945A (zh) 2019-09-03
LT3559010T (lt) 2022-10-10
PL3559010T3 (pl) 2022-11-21
BR112019012972A2 (pt) 2019-12-31
HRP20221067T1 (hr) 2022-11-25
KR102609373B1 (ko) 2023-12-01
JP7294661B2 (ja) 2023-06-20
IL267557A (en) 2019-08-29
CN110198945B (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
PE20160540A1 (es) Inhibidores de bromodominios
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20140207A1 (es) Composiciones y metodos para modular el fxr
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
UY34722A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8- hidroxiquinolin-2(1h)-ona
CO2017002266A2 (es) Derivados de 5-[3-metil-2-[(4-metillsulfonilpiperazin-1-il)metil]-7-morfolinotieno [2,3-c] piridinil como inhibidores de la quinasa pi3
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
DK3298008T3 (da) Krystallinsk form af forbindelsen (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-1,2-diol
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
UY34194A (es) ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
MY180730A (en) Azole benzene derivative and crystalline form thereof
IL264574B (en) A method for the production of 4-disubstituted 3,2-dihydro-1-benzofuran derivatives by silylation of 2-(2-diazonium-6-disubstituted phenyl)ethanol salts
UA88441U (en) Methyl 2-((5-(3,4,5-trimethoxyphenyl)-1h-1,2,4-triazole-3-yl)thio)acetate exhibiting antihypoxic activity
PE20091681A1 (es) 3-indazolil-4-piridilisotiazoles
UA88316U (en) Piperidin-1-ium 2-(5-(4-methoxyphenyl)-1h-1,2,4-triazole-3-ylthio)acetate exhibiting actoprotector activity